# Christopher J. Sweeney

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/christopher-j-sweeney/

## Facts

| Field | Value |
| --- | --- |
| Citations | 30,983 |
| Field | Prostate Cancer Treatment and Research |
| h-index | 87 |
| i10-index | 309 |
| Last Known Institution | Australian Institute of Business |
| OpenAlex ID | https://openalex.org/A5002909668 |
| ORCID iD | https://orcid.org/0000-0002-0398-6018 |
| Works | 832 |

## Researcher papers

- [Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer](https://scholariq.org/papers/chemohormonal-therapy-in-metastatic-hormone-sensitive-prostate-cancer/)
- [Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer](https://scholariq.org/papers/enzalutamide-with-standard-first-line-therapy-in-metastatic-prostate-cancer/)
- [Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial](https://scholariq.org/papers/chemohormonal-therapy-in-metastatic-hormone-sensitive-prostate-cancer-long-term/)
- [Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017](https://scholariq.org/papers/management-of-patients-with-advanced-prostate-cancer-the-report-of-the-advanced/)
- [Enhancer RNAs participate in androgen receptor-driven looping that selectively enhances gene activation](https://scholariq.org/papers/enhancer-rnas-participate-in-androgen-receptor-driven-looping-that-selectively/)
- [Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019](https://scholariq.org/papers/management-of-patients-with-advanced-prostate-cancer-report-of-the-advanced/)
- [Active Surveillance Compared With Initial Treatment for Men With Low-Risk Prostate Cancer](https://scholariq.org/papers/active-surveillance-compared-with-initial-treatment-for-men-with-low-risk/)
- [Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022](https://scholariq.org/papers/management-of-patients-with-advanced-prostate-cancer-metastatic-and-or/)
- [Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data](https://scholariq.org/papers/prediction-of-overall-survival-for-patients-with-metastatic-castration-resistant/)

## Researcher topics

- [Prostate Cancer Treatment and Research](https://scholariq.org/topics/prostate-cancer-treatment-and-research/)
- [Prostate Cancer Diagnosis and Treatment](https://scholariq.org/topics/prostate-cancer-diagnosis-and-treatment/)
- [Radiopharmaceutical Chemistry and Applications](https://scholariq.org/topics/radiopharmaceutical-chemistry-and-applications/)
- [Cancer, Lipids, and Metabolism](https://scholariq.org/topics/cancer-lipids-and-metabolism/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Researcher university

- [Australian Institute of Business](https://scholariq.org/institutions/australian-institute-of-business/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.